Brought to you by 
Ori (now Replicor) seed round funds DNA replication technology
03 Aug 1999
Executive Summary
Ori Biotech, a Montreal start-up (since renamed Replicor Inc.; developing gene delivery systems), raised seed money of $450,000 from the venture capital firm T2C2 to fund development of platform technologies for regulating DNA replication.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com